In vitro leishmanicidal, antibacterial and antitumour potential of anhydrocochlioquinone A obtained from the fungus Cochliobolus sp by Campos, Fernanda F et al.
In vitro leishmanicidal, antibacterial and antitumour potential
of anhydrocochlioquinone A obtained from the fungus
Cochliobolus sp.
FERNANDA F CAMPOS1,2*, JONAS P RAMOS3, DJALMA M DE OLIVEIRA4, TÂNIA M A ALVES2,
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The bioassay-guided fractionation of the ethyl acetate extract of the fungus Cochliobolus sp. highlighted leishmanicidal
activity and allowed for anhydrocochlioquinone A (ANDC-A) isolation. MS, 1D and 2D NMR spectra of this compound
were in agreement with those published in the literature. ANDC-A exhibited leishmanicidal activity with EC50 value of
22.4 lg/mL (44 lM) and, when submitted to the microdilution assay against Gram-positive and Gram-negative bacteria,
showed a minimal inhibitory concentration against Staphylococcus aureus ATCC 25295 of 128 lg/mL (248.7 lM). It was
also active against five human cancer cell lines, showing IC50 values from 5.4 to 20.3 lM. ANDC-A demonstrated a
differential selectivity for HL-60 (SI 5.5) and THP-1 (SI 4.3) cell lines in comparison with Vero cells and was more
selective than cisplatin and doxorubicin against MCF-7 cell line in comparison with human peripheral blood mononuclear
cells. ANDC-A was able to eradicate clonogenic tumour cells at concentrations of 20 and 50 lM and induced apoptosis in
all tumour cell lines at 20 lM. These results suggest that ANDC-A might be used as a biochemical tool in the study of
tumour cells biochemistry as well as an anticancer agent with durable effects on tumours.
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1. Introduction
Leishmaniases are diseases caused by protozoan parasites
belonging to more than 20 Leishmania species that are
transmitted to humans by the bites of infected female phle-
botomine sandflies (WHO 2017). In the Americas, a total of
51,098 cases of cutaneous leishmaniasis and mucosal form
were reported in 2014, with an incidence rate of 19.76 cases
per 100,000 inhabitants, being that Brazil (20,418 cases),
Colombia (11,586) and Peru (6231) held 75% of all cases
(PAHO 2016). The main forms of the disease, i.e. cutaneous,
visceral and mucocutaneous, affect poor and vulnerable
groups in the world, hence remaining a leading cause of
morbidity and mortality in most of the endemic and poor
countries (WHO 2010; Savoia 2015); furthermore, most of
antileishmanial drugs were introduced many decades ago
(Ehrenberg and Ault 2005; WHO 2010).
Antibiotics have increased the life span and guaranteed
the success of some advanced medical practices (Gould and
Bal 2013). However, the emergence of resistant bacteria is
occurring worldwide, jeopardizing the efficacy of antibi-
otics, mainly due to (Barlett et al. 2013; Ventola 2015):
(i) overuse, (ii) inappropriate prescribing, (iii) addressing
antibiotic abuse in farm animal and (iv) drop in development
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of newer antibiotics. In relation to the last item, Ventola
(2015) said that the number of new antibiotics developed
and approved has decreased steadily over the past three
decades (although four new drugs were approved in 2014),
leaving fewer options to treat resistant bacteria.
The population growth and ageing combined with life-
style risk factors have increased the number of cases of
cancer. Currently, cancer is a leading cause of death and
disability in low-income and middle-income countries, and
the treatments of some cancer types are palliative and remain
neglected compared with other diseases (Farmer et al. 2010).
On the other hand, uniformly the cancers are fatal, often as a
result of development of resistance to traditional drugs
(Housman et al. 2014). Thus, to overcome the chemoresis-
tance to current therapies and improve patient outcome,
novel treatment agents are highly needed.
In turn, microorganisms have been studied as source of
many chemotherapeutics, and amongst them, fungi can be
promising sources. In the present work, the bioassay-guided
fractionation of the ethyl acetate extract from the endophytic
fungus Cochliobolus sp. resulted in the isolation of anhy-
drocochlioquinone A (ANDC-A), which was then tested for
its leishmanicidal and antimicrobial activities. In addition, its
cytotoxic effects on five human tumour cells and differential
toxicity in comparison with Vero cells and PBMC were
assessed. In previous study, Campos et al. (2008) demon-
strated that the chromatographic fractionation of the extract
of Cochliobolus sp. was validated as a drug target for Try-
panosoma cruzi. These authors identified Cochlioquinone A
and isocochlioquinone A as enzyme inhibitors that showed
activity in the assay with Leishmania amazonensis. These
results stimulated us to search and isolate new bioactive
compounds from this fungus with leishmanicidal, antibac-
terial and antitumour potential.
2. Materials and methods
2.1 Microorganism maintenance and extraction
of secondary metabolites
The endophytic fungus Cochliobolus sp. was grown and
maintained in potato dextrose agar (PDA) as previously
described by Campos et al. (2008). After the inoculum,
dishes were stored at 4 C and subcultured every two weeks.
The fungus was grown on PDA in 1000 Petri dishes and
extracted with ethyl acetate at room temperature for 48 h.
The organic phase was filtered and the solvent evaporated
under vacuum in a rotary-evaporator at 45C (model 4000,
Laborota Heidolph, Germany). Residual solvent was elimi-
nated after vacuum centrifugation at 40C using a Spress
SpeedVac vacuum centrifuge (Thermo-Savant SPD SC250
Express, Holbrook, NY, USA). Sample for leishmanicidal
(10 mg mL-1), antimicrobial (according to MIC
determination described in section 2.5) and cytotoxicity (10
mg mL-1) testing were prepared in 0.5% aqueous dimethyl
sulfoxide.
2.2 Chromatographic fractionation of the extract
An aliquot of the organic extract (3.0 g) was subjected to
preparative purification by medium pressure liquid chro-
matography (MPLC) with methanol:water (10:90?100:0)
as a gradient elution system. A total of 148 fractions of 50
mL each were collected. They were pooled into 24 groups
based on their similarity, as assessed by thin-layer chro-
matography after elution with a 95:5 dichlor-
omethane:methanol mixture. Group 22 (121 mg) was active
in in vitro leishmanicidal screening, and its purity by HPLC
analysis was 99%.
The MPLC was carried out using a preparative C18
(LiChroprep RP-18, 40–63 lM, Merck, Darmstadt, Ger-
many) reverse-phase column (250920 mm) and a LC8-AD
pump (Shimadzu, Kyoto, Japan) at 20 mL/min flow rate.
Thin-layer chromatographic analyses were conducted on
pre-coated commercial silica gel G-60/F254 (Merck) plates.
The spots were visualized after spraying the plate with a 1:1
mixture of 1% (w/v) vanillin and 10% (v/v) H2SO4 ethanolic
solutions followed by heating at 100C for 5–10 min.
Analytical RP-HPLC analyses were developed in a HPLC
system (Shimadzu) equipped with a LC6-AD pump and a
SPD M-10A VP Diode Array.
2.3 Structure elucidation of the isolated bioactive
compound
The bioactive compound isolated from group 22 was dis-
solved in perdeuterated solvent containing 0.1% tetram-
ethylsilane as the internal chemical shift standard, and
spectral data were obtained according to Campos et al.
(2008). The mass spectra (MS) were recorded by a mass
spectrometer, model LCQ Advantage (Thermo Finnigan,
San Jose, CA, USA), equipped with an electrospray ion
(ESI) source, and the NMR ones by a spectrometer, model
DRX 400 (Bruker, Rheinstetten, Germany).
The isolated bioactive compound is a red wine amorphous
solid with UVmax absorption in methanol of 199, 273 485
nm. The electrospray ionization mass spectra (ESI-MS)
analysis exhibited quasi-molecular ion peaks at m/z 537.3
[M?Na]? and 477.1 [M?Na-Ac]?). 1H NMR spectra data
(CDCl3, 400 MHz) were: dH 0.84 (3H, m, H-1), 0.86 (3H, d,
J 7.0 Hz, H-28), 1.08 (1H, dd, J 7.0, 4.5 Hz, H-2a), 1.13
(3H, br. s, H-25), 1.13 (3H, d, J 6.5 Hz, H-27),, 1.19 (3H, br.
s, H-23), 1.20 (3 H, br. s, H-24), 1.42-1.46 (1H, m, H-2b),
1.47-1.55, (1H, m, H-3), 1.49-1.53 (1H, m, H-19a), 1.54-
1.62 (1H, m, H-20b), 1.55 (3H, br. s, H-26), 1.67-1.72 (1H,
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m, H-16b), 1.70-1.75 (1H, m, H-20a), 1.78-1.85 (1H, m,
H-16a), 2.02 (1H, m, H-15a), 2.05 (3H, br s., H-30), 2.11
(1H, ddd, J 12.0, 12.0, 5.0 Hz, H-19b), 2.31 (1H, dt, J 13.5,
3.5, 3.5 Hz H-15b), 3.19 (1H, br. dd, J 12.0, 4.0, Hz, H-21),
3.20 (1H, dd, J 11.5, 4.0 Hz, H-17), 3.40 (1H, br. dddd,
J 6.5, 6.5, 6.5 and 6.5 Hz), 4.93 (1H, dd, J 6.5, 5.5 Hz, H-4),
6.33 (1H, s, H-12) and 6.63 (1H, s, H-11). On the other
hand, 13C NMR (CD3OD, 100 MHz) spectra showed: dC
11.09 (C-1), 15.46 (C-28), 18.26 (C-27), 20.19 (C-25), 20.85
(C-30), 21.65 (C-20), 23.85(C-23), 23.95 (C-2), 24.51 (C-
16), 26.07 (C-24), 27.05 (C-26), 32.64 (C-5), 34.83 (C-19),
36.43 (C-3), 37.85 (C-15), 38.64 (C-18), 71.83 (C-22),
80.03 (C-4), 81.09 (C-17), 81.51 (C-14), 84.62 (C-21),
110.55 (C-12), 117.17 (C-9), 132.88 (C-11), 147.56 (C-13),
148.95 (C-6), 148.95 (C-8), 170.61 (C-29), 181.16 (C-7),
184.98 (C-10).
2.4 Leishmanicidal activity
Leishmanicidal activity was determined using promastigotes
of Leishmania amazonensis IFLA/BR/196/PH-8 obtained
from lesions of infected hamsters (Callahan et al. 1997).
Parasites were differentiated into amastigotes by rising
temperature from 26 to 32C and lowering the pH of the
Schneider’s medium from 7.2 to 6.0. After 7 days,
amastigote density was adjusted to 19108 parasites per mL,
and 90 lL of this suspension were added to each well of
96-well plates. Ten microliters of test samples and controls
solutions were added to obtain the desired concentrations.
Plates were incubated at 32C for 72 h, and then cells via-
bility was determined by the methyl thiazolyl tetrazolium
(MTT) assay (Teixeira et al. 2002). Results were expressed
as percent inhibition in relation to the controls without drug
according to Campos et al. (2008). Amphotericin B at 0.2
lg/mL was used as a positive drug control. The effective
concentration to kill 50% of the parasites (EC50) was
obtained from dose-response curves fit of two or more
independent experimental datasets to a four-parameter
logistic dose-response (Campos et al. 2008) using the soft-
ware GraphPad Prism (version 4.03, CA, USA).
2.5 Antimicrobial activity
Antimicrobial activity either of the Cochliobolus sp. extract
or the ANDC-A-rich fraction obtained by MPLC was tested
against six target bacterial strains, namely Staphylococcus
aureus ATCC 25295, Escherichia coli ATCC 18804, Sal-
monella typhimurium ATCC14028, Pseudomonas aerugi-
nosa ATCC27853, Klebsiella oxytoca ATCC 49131 and
Listeria monocytogenes ATCC 19115. Bacterial strains were
maintained on Brain Heart Infusion agar according Campos
et al. (2008). Mueller Hinton broth was prepared in
accordance with the CLSI document M7-A6 and used for
Minimal Inhibitory Concentration (MIC) bacterial assays
according to NCCLS (NCCLS 2003) with modifications
(Campos et al. 2008).
2.6 Cell line assays
2.6.1 Human tumour and Vero cell lines: The in vitro
cytotoxicity activity of the ANDC-A-rich fraction obtained
by MPLC was tested against five different human tumour
cell lines, namely human promyelocytic leukemia cell line
(HL-60), human immortalized line of T lymphocyte cells
(Jurkat), acute monocytic leukemia cell line (THP-1), human
breast cancer cell line (MCF-7), and human colorectal car-
cinoma cell line (HCT-116). In addition, normal cells of
African green monkey kidney line (Vero) and human
peripheral blood mononuclear cells (PBMC) were used as
models. The cells (except PBMC) were maintained in Ros-
well Park Memorial Institute (RPMI) 1640 medium or
Dulbecco’s Modified Eagle Medium (D-MEM) supple-
mented with 100 IU/mL penicillin and 100 lg/mL strepto-
mycin. Leukemia cells were cultured in RPMI 1640 medium
supplemented with 10% (v/v) fetal bovine serum enriched
with 2 mM L-glutamine.
Cell lines were inoculated at 19104 cells (MCF-7, HCT
and Vero), 59104 cells (HL-60) and 19105 cells (Jurkat and
THP-1) per well. Plates were pre-incubated for 24 h at 37 C
before the addition of the test compounds. The half maximal
inhibitory concentration (IC50) was determined using non-
serial eight dilutions (from 100 to 1.5 lg/mL). All cell
cultures were incubated in a 5% CO2/95% air-humidified
atmosphere at 37 C for 48 h. Dimethyl sulfoxide at con-
centration of 0.5% (v/v) was used as negative control. Cell
viability was estimated using MTT (Monks et al. 1991).
Etoposide, doxorubicin and cisplatin were used as positive
controls. The selectivity indexes (SI) were determined as the
ratios of the IC50 values for tumour cell lines to those for
normal (PBMC and Vero) cells (Badisa et al. 2009).
2.6.2 Human peripheral blood mononuclear cells: Human
peripheral blood mononuclear cells (PBMC) were obtained
from healthy adult volunteers of both sexes (HEMOMINAS,
protocol n. 105/2004) by centrifugation of heparinized
venous blood over Ficoll cushion (Pinto et al. 2011). PBMC
were collected from the interphase after Ficoll separation and
washed thrice in RPMI 1640 medium before further pro-
cessing. Cells were cultured in complete RPMI 1640 med-
ium, supplemented with 5% (v/v) heat-inactivated, pooled
human serum type AB and 2.0 mM L-glutamine, containing
1,000 U/mL penicillin, 1,000 lg/mL streptomycin and 25
lg/mL fungisone.
Briefly 19106 cells/mL (1.5 x 105 cells per well) were
seed in flat-bottomed microtiter plates. Cultures were
In vitro potential of anhydrocochlioquinone A 659
stimulated with 2.5 lg/mL phytohemagglutinin (PHA) and
incubated for 72 h at 37C in a 5% CO2/95% air-humidified
atmosphere (Gazzinelli et al. 1983). Cell proliferation was
determined using a MTT-based colorimetric assay (Jiang and
Xu, 2003). The half maximal inhibitory concentration (IC50)
was determined using non-serial eight dilutions (from 100 to
1.5 lg/mL).
2.6.3 Determination of subdiploid DNA content: Quantifi-
cation of subdiploid DNA-content as indicative of DNA
fragmentation by apoptosis was performed by propidium
iodide (PI) staining and flow cytometry analysis (Nicoletti
et al. 1991). All tumour cells were treated with ANDC-A at
final concentration of 20 lM and incubated in a 5% CO2/
95% air-humidified atmosphere at 37C for 24 h. After-
wards, cells were centrifuged, resuspended in a hypotonic
fluorochrome solution (50 lg/mL PI in 0.1% sodium citrate
plus 0.1% Triton X-100) and incubated at 4C for 4 h. The
PI fluorescence of 10.000 individual nuclei was measured
using a FACScan flow cytometer (Becton Dickinson, San
Jose, CA, USA). Data were analysed by the FlowJo software
(TreeStar Inc, Ashland, OR, USA).
2.6.4 Clonogenic cell survival assay: MCF-7 and HCT-116
cells were inoculated in D-MEM up to a concentration of
200 cells per mL. Then, 2.0 mL of the resulting suspensions
were seeded into each well of six-well plates. After 4 h, they
were treated with vehicle control (0.5% v/v DMSO per well)
or with 20 or 50 lM ANDC-A. After 24 h, the medium was
replaced by 4.0 mL of fresh medium to stop the treatment.
After 14 days, cells were stained with crystal violet, and
colonies with up to 50 cells were counted. Data were
expressed as survival fraction (Mordant et al. 2010).
2.7 Statistical analysis
All measurements were performed in two independent
experiments carried out in triplicate. The significance of
some variations was presented in the form of probability
values (*p\0.05, **p\0.01, ***p\0.001 or nsp[0.05, where
ns means ‘not significant’) using the Student’s t-test (Soft-
ware GraphPad Prism, version 4.03, CA, USA).
3. Results
The ethyl acetate extract of Cochliobolus sp. was fraction-
ated by reverse-phase MPLC, and the fraction 22 that
showed a single major compound was active against
axenically grown Leishmania amazonensis amastigotes,
exhibiting 78% inhibition at 20 lg/mL (test screening). This
compond showed MS, 1D and 2D NMR spectra in full
agreement with those reported for anhydrocochlioquinone A
(ANDC-A) (figure 1) (Phuwapraisirisan et al. 2007) and an
EC50 value of 22 lg/mL (42.7 lM) (table 1) in the in-vitro
leishmanicidal assay. This value is almost 100 times higher
than that obtained for amphotericin and approximately 4
times lower than that obtained for the Cochliobolus sp.
extract.
ANDC-A was also evaluated for its activity against sev-
eral opportunistic bacterial strains (table 1) according to the
susceptibility test. The results showed that ANDC-A was
only partially active against Staphylococcus aureus ATCC
25295, with a MIC value of 128 lg/mL (248.7 lM), while
for the other bacteria the MIC was higher than 256 lg/mL
(497.4 lM). In turn, the extract of Cochliobolus sp. showed
no activity against the tested bacteria (MIC[256 lg/mL).
When ANDC-A was tested against a panel of five lines of
human cancer cells, it was able to reduce the viability of all
them and showed IC50 (effective concentration to kill 50%
of the parasites) values ranging from 5.5 to 20.3 lM
(table 2). In the same assay, etoposide, drugs used in clinic
to treat leukemia, showed IC50\3 lM for HL-60 and THP-1
cells lines and[100 lM for the other cells lines. Doxoru-
bicin, a drug used in breast cancer, showed IC50 of 3.61±2.6
lM and 10.93±2.35 lM for MCF-7 and HCT-116 cell lines,
respectively (table 2), while cisplatin, an adjuvant
chemotherapic to treat solid tumours, showed IC50[100 and
\40 lM for MCF-7 and HCT-116 cancer cells, respectively.
ANDC-A and control drugs were also tested for their
cytotoxicity against non-tumour cells, exhibiting IC50 values
of 29.9 and 19.3 lM for Vero cells and normal lymphocytes
(PBMC), respectively (table 2), as well as a differential
selectivity for HL-60 and THP-1 cell lines in comparison to
Vero cells (SIM of 5.5 and 4.3, respectively) and to human
cells (SIH of 3.5 and 2.8, respectively). Whereas these SI
values were one order of magnitude lower than those
exhibited by etoposide (55.5 and 47.6 for THP-1 and HL-60,
respectively), for Jukart cells those of both ANDC-A and
etoposide as control were\2.0. For both MCF-7 and HCT-
116 cells, the ANDC-A SIM values ([2.0) were higher than
those of cisplatin (B1.9), but lower than those of doxoru-
bicin (C5.7), while the corresponding SIH values, including
those of doxorubicin and cisplatin as controls, were all\2.0.
As illustrated in figure 2, after 24 h-treatment at concen-
tration of 20 lM, ANDC-A was also able to significantly
induce a statistically significant increase in subdiploid DNA
content associated with DNA fragmentation in all cell lines
compared with 0.5% DMSO used as a control (p\0.0001).
The same significant difference was observed when com-
paring the etoposide (HL-50, Jukart and THP-1) and dox-
orubicin (MCF-7) controls with DMSO. Except for HL-60
cells, the percentage of subdiploid DNA was higher in the
presence of ANDC-A when compared to controls. The
highest values of DNA fragmentation ([70%) induced by
ANDC-A were observed in Jurkat and THP-1 and MCF-7
cells lines.
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Finally, the treatment of MCF-7 and HCT-116 cells with
ANDC-A at concentrations of 20 and 50 lM for 24 h (fig-
ure 3) resulted in a strong decrease of survival fraction of
viable cells, eradicating clonogenic cells with self-renewal
capacity.
4. Discussion
Although ANDC-A has been isolated in large quantity from
the extract in the present study, the compounds closely
related to it, i.e. cochlioquinone A and isocochlioquinone A
(figure 1), were detected neither by TLC nor by HPLC. This
finding may be due to any biochemical alteration of the
fungal isolate as a result of storage and/or of several mycelial
transfers at different times under different conditions (Kale
et al. 1994).
ANDC-A was less active than cochlioquinone A and iso-
cochlioquinone A, which exhibited EC50 values of 1.7 lM
and 4.1 lM, respectively, in the same assay with axenically
grown L. amazonensis amastigotes (Campos et al. 2008).
According to the literature, cochlioquinone A has
antimicrobial potential against Staphylococcus aureus CCT
4295 (MIC[15 ppm), Bacillus subtilis CCT 0089 (MIC[15
ppm) and Apergillus niger CCT 1435 (MIC[250 ppm)
(Campos et al. 2008). On the other hand, when tested
according to the microdilution assay against either Gram-
positive or Gram-negative bacteria, ANDC-A exhibited
weak activity against S. aureus (Bicalho et al. 2013).
Accordingly, in the present work ANDC-A showed a partial
activity against S. aureus. As shown in figure 1, compared
with cochlioquinone A, ANDC-A has a double bond in
positions 12 and 13 as a result of the loss of one water
molecule, which may have been responsible for such dif-
ference in biological activity (Pinto et al. 2014).
To the best of our knowledge, ANDC-A was shown to
inhibit the growth of HeLa cells (IC50=5.9 lg/mL, corre-
sponding to 11.48 lM) (Phuwapraisirisan et al. 2007). When
ANDC-A was tested in the present work against five human
cancer cell lines, it was active in the same concentration
range or below than 25 lM, thus confirming the potential of
this substance for antitumour therapies.
Table 1. In vitro leishmanicidal and antimicrobial activities of Cochliobolus sp. extract and anhydrocochlioquinone A compared to those





L.Ac S.Ad E.Ce S.Tf P.Ag K.Oh L.Mi
Cochliobolus extract 87 ± 3*** [ 256 [ 256 [ 256 [ 256 [ 256 [ 256
ANDC-Aj 22 ± 2** 128 [ 256 [ 256 [ 256 [ 256 [ 256
Chloramphenicol NAk 16 8 16 8 8 8
Amphotericin B 0.024±0.004 NA NA NA NA NA NA
a EC50, half effective concentration;
bMIC, minimal inhibitory concentration; cL.A, Leishmania amazonensis IFLA/BR/196/PH-8; dS.A, Sta-
phylococcus aureus ATCC 25295; eE.C, Escherichia coli ATCC 18804; fS.T, Salmonella typhimurium ATCC14028; gP.A, Pseudomonas aerug-
inosa ATCC27853; hK.O, Klebsiella oxytoca ATCC 49131; iL.M, Listeria monocytogenes ATCC 19115; jANDC-A, anhydrocochlioquinone A;
kNA, not applicable; **p\0.01 or ***p\0.001, statistically significant EC50 values when compared with Amphotericin B as control by the
Student’s t-test
Figure 1. Chemical structure of ANDC-A isolated from Cochliobolus sp.
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As is well known, the selectivity index (SI) of a com-
pound is an important parameter that provides a measure of
its potential in vivo toxicity, in that compounds with SI[2
are considered to be selective against tumour cells (Badisa
et al. 2009). ANDC-A showed SI[2 only for HL-60 and
THP-1 cell lines compared with monkey (Vero) and human
Table 2. In vitro cytotoxic activity of anhydrocochlioquinone A and control drugs against five tumour cell lines expressed as half
maximal inhibitory concentration (IC50, lM/mL) and selectivity indexes (SI, dimensionless) using IC50 values for normal monkey (Vero,
SIM)
a or human (PBMC, SIH)
b cell models
Tumour cells
ANDC-Ac Etoposided Doxorubicine Cisplatinf
IC50 SIM SIH IC50 SIM SIH IC50 SIM SIH IC50 SIM SIH
HL-60g 5.48 ± 2.54 5.5 3.5 1.79 ± 0.72ns 55.5 55.5 NDl ND ND ND ND ND
Jukath 20.34 ± 2.21 1.5 1.0 [100.00*** \1.0 \1.0 ND ND ND ND ND ND
THP-1i 6.91 ± 0.29 4.3 2.8 2.10 ± 1.18* 47.6 47.6 ND ND ND ND ND ND
MCF-7j 13.31 ± 3.07 2.2 1.4 [100.00*** Im I 10.93 ± 2.35ns 5.7 0.6 [100.00*** 0.7 0.03
HCT-116k 11.00 ± 4.18 2.7 1.8 [100.00*** I I 3.61 ± 2.60ns 15.8 1.8 38.05 ± 5.27* 1.9 0.09
Veroa 29.93 ± 5.83 NAn NA [100.00*** NA NA 57.24 ± 6.65* NA NA 76.69 ± 16.48* NA NA
PBMCb 19.29 ± 2.31 NA NA [100.00*** NA NA 6.4 ± 0.3* NA NA 3.43 ± 1.18* NA NA
a Vero, African green monkey kidney line; bPBMC, peripheral blood mononuclear cells; cANDC-A, anhydrocochlioquinone A; dControl, drug
used in clinic to treat leukemia; eControl, drug used in clinic to treat breast cancer; fControl, adjuvant chemotherapic to treat solid tumours; gHL-60,
human promyelocytic leukemia; hJurkat, human immortalized line of T lymphocyte; iTHP-1, acute monocytic line; jMCF-7, human breast cancer
line; kHCT-116, human colorectal carcinoma line; lND, not determined; mI, inactive; nNA, not applicable; *p\0.05 or ***p\0.001, statistically
significant IC50 values when compared with the ANDC-A treatment for each cell line by the Student-t test; ns, not statistically significant difference































































Figure 2. Increase of subdiploid DNA content in human tumour cells induced by ANDC-A. ANDC-A was incubated with the different
cell lines for 24 h at 37C and 5% CO2. The subdiploid DNA content was used as indicative of DNA fragmentation after labeling with
propidine iodide and flow cytometry analysis. The mean data (grey bar) and error bar are representative data of two independent
experiments carried out in triplicate. Either ANDC-A or control drugs of clinical use, namely etoposide (ETO), cisplatin (CIS) and
doxorubicin (DOXO), were used at concentration of 20 lM. ***Statistically significant values (p\0.0001).
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cells (PBMC) as models. To provide a comparison basis,
4-hydroxy tamoxifen, an antiestrogen used in the treatment
of human breast cancer, exhibited SI=1.29 against MCF-7
cells in comparison with CRL-1439 normal liver cell line
(Badisa et al. 2009). Moreover, although ANDC-A showed
SI\2 for Jurkat, MCF-7 and HCT-116 cell lines in com-
parison with PBMC, it was more selective than doxorubicin
and cisplatin, two drugs in clinical use.
Recently, ANDC-A isolated together with other three
cochlioquinone derivatives from the ethyl acetate extract of
the phytopathogenic fungus Bipolaris luttrellii was the only
compound able to induce apoptosis and caspase activity in a
dose-dependent manner (10–30 lM) in HCT116 cells, as the
likely result of Bcl-2 downregulation and cytochrome c
release from mitochondria (Qi et al. 2014). It has been
demonstrated that resistance to chemotherapy mainly
involves apoptosis, which is a potential therapeutic target for
cancer treatment (Nicholson 2000; Fesik 2005). Also, in our
tests the treatment with 20 lM ANDC-A was able to induce
DNA fragmentation both in leukemic and solid lines, with
the strongest effect on Jurkat cell line.
Even after post-treatment with drugs, senescent cancer
cells can maintain their membrane intact and remain
metabolically active for a long time. These cells may then be
considered as ‘‘survivors’’ in short-term assays of cell via-
bility loss such as MTT. Clonogenic assay is suitable to
determine all modes of cell death and includes both early
and late responses such as delayed growth arrest. For these
reasons, it is considered the ‘‘gold standard’’ assay for the
assessment of cytotoxicity (Mirzayans et al. 2007). ANDC-
A was able to eradicate all MCF-7 and HCT-116 clonogenic
cells at concentration of 20 lM. This activity is quite
important to achieve durable results in anticancer therapy,
because it requires effective elimination of subpopulations of
cancer cells that otherwise could remain unaffected.
In this study we showed that anhydrocochlioquinone A
markedly reduces cell viability of tumour cells from different
cancer models (leukemia and solid tumour) and is able to
induce apoptosis in all cell lines. Moreover, it was shown to
eradicate cells with self-renewal capacity, suggesting good
effectiveness and antitumour potential.
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